Related Experiment Video
Updated: Feb 28, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Urolithins impair cell proliferation, arrest the cell cycle and induce apoptosis in UMUC3 bladder cancer cells
Joana Liberal1,2, Anália Carmo3,4, Célia Gomes5,6
1Escola Superior de Saúde Dr. Lopes Dias, Instituto Politécnico de Castelo Branco, Campus da Talagueira, Avenida do Empresário, 6000-767, Castelo Branco, Portugal. joanaliberal@gmail.com.
Abstract:
Ellagitannins have been gaining attention as potential anticancer molecules. However, the low bioavailability of ellagitannins and their extensive metabolization in the gastrointestinal tract into ellagic acid and urolithins suggest that the health benefits of consuming ellagitannins rely on the direct effects of their metabolites. Recently, chemopreventive and chemotherapeutic activities were ascribed to urolithins. Nonetheless, there is still a need to screen and evaluate the selectivity of these molecules and to elucidate their cellular mechanisms of action. Therefore, this work focused on the antiproliferative effects of urolithins A, B and C and ellagic acid on different human tumor cell lines. The evaluation of cell viability and the determination of the half-maximal inhibitory concentrations indicated that the sensitivity to the studied urolithins varied markedly between the different cell lines, with the bladder cancer cells (UMUC3) being the most susceptible. In UMUC3 cells, urolithin A was the most active molecule, promoting cell cycle arrest at the G2/M checkpoint, increasing apoptotic cell death and inhibiting PI3K/Akt and MAPK signaling. Overall, the present study emphasizes the chemopreventive/chemotherapeutic potential of urolithins, highlighting the stronger effects of urolithin A and its potential to target transitional bladder cancer cells.
Insights
Urolithins, metabolites of ellagitannins, show anticancer potential. Urolithin A effectively inhibited bladder cancer cell growth by inducing cell cycle arrest and apoptosis, suggesting its therapeutic promise.
Area of Science:
- * Biochemistry and Molecular Biology
- * Cancer Research
- * Nutraceuticals and Natural Products
Background:
- * Ellagitannins are natural compounds with potential health benefits, but their low bioavailability necessitates understanding the role of their metabolites.
- * Urolithins, derived from ellagitannins, are increasingly recognized for their chemopreventive and chemotherapeutic properties.
- * Further research is needed to evaluate the selectivity and mechanisms of action of urolithins against various cancer types.
Purpose of the Study:
- * To investigate the antiproliferative effects of urolithins A, B, and C, and ellagic acid on diverse human tumor cell lines.
- * To identify the most sensitive cancer cell lines to urolithin treatment.
- * To elucidate the cellular mechanisms underlying the activity of the most potent urolithin in susceptible cancer cells.
Main Methods:
- * Cell viability assays were performed to determine the half-maximal inhibitory concentrations (IC50) of urolithins and ellagic acid.
- * Flow cytometry was used to analyze cell cycle distribution and apoptosis.
- * Western blotting was employed to assess the impact on PI3K/Akt and MAPK signaling pathways.
Main Results:
- * Significant variability in sensitivity to urolithins was observed across different human tumor cell lines.
- * Bladder cancer cells (UMUC3) exhibited the highest susceptibility to the tested urolithins.
- * Urolithin A demonstrated the strongest activity in UMUC3 cells, inducing G2/M cell cycle arrest, promoting apoptosis, and inhibiting PI3K/Akt and MAPK signaling pathways.
Conclusions:
- * Urolithins possess significant antiproliferative and anticancer potential, with varying efficacy depending on the cell type.
- * Urolithin A is a particularly potent agent against transitional bladder cancer cells.
- * The findings support the chemotherapeutic and chemopreventive roles of urolithins, especially urolithin A, in targeting bladder cancer.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi I: Introduction
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Urinary Tract Calculi VI: Surgical Management
Urinary Tract Calculi V: Nursing Management

